Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

E.U. approval for NovoMix 30 label extension

May 4, 2006

Enrollment completed in phase IIb obesity study of AOD-9604

May 4, 2006

Amicus files to begin phase I studies of AT-2101 in Gaucher's disease

May 4, 2006

Emisphere to receive milestone payment for use of eligen in Novartis program

May 4, 2006

AERx iDMS phase III program set to reopen

May 4, 2006

Acomplia recommended for approval in E.U.

May 3, 2006

FibroGen licenses oral HIF-PH inhibitors to Astellas

May 3, 2006

ApoB-100-specific ASO more effective than MTTP-specific ASO in lowering cholesterol in mice

May 3, 2006

AstraZeneca presents a new glucokinase activator

May 3, 2006

Novel agents for treating diabetes disclosed in recent patents

May 2, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...